Aptevo Therapeutics Inc. cash flow to debt ratio of -552.86% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aptevo Therapeutics Inc.'s free cash flow has decreased 7.60% from $-23.79M last year to $-25.59M, signaling decreasing performance

Aptevo Therapeutics Inc.'s debt to equity ratio is 0.38, which means that the company's assets are healthy financed, signaling financial stability.

Aptevo Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.97 last year to 0.38 today, signaling strengthened financials

Aptevo Therapeutics Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Aptevo Therapeutics Inc.'s latest filing, so interest coverage cannot be calculated.

Aptevo Therapeutics Inc. has insufficient data to evaluate this check.

Aptevo Therapeutics Inc.'s short-term assets of $23.08M exceed its short-term liabilities of $6.05M

Aptevo Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aptevo Therapeutics Inc.'s return on equity of -198.50%, is lower than 15.00%, indicating bad performance

Aptevo Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aptevo Therapeutics Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Aptevo Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aptevo Therapeutics Inc. has negative free cash flow, indicating cash burn

Aptevo Therapeutics Inc.'s yearly earnings has decreased 7.61% since last year from $-24.13M to $-25.97M, signaling decreasing performance

Aptevo Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -166.33% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aptevo Therapeutics Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Aptevo Therapeutics Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Aptevo Therapeutics Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Aptevo Therapeutics Inc. has insufficient data to evaluate this check.

Aptevo Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aptevo Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aptevo Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aptevo Therapeutics Inc. has insufficient data to evaluate this check.

Aptevo Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aptevo Therapeutics Inc. has a price-to-book ratio of 0.37x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aptevo Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue